In situations where a biased sender provides verifiable information to a receiver, I study how strategic reporting affects the incentives to search for information. Research provides series of signals that can be used selectively in reporting. I show that the sender is strictly worse off whenhis research effort is not observed by the receiver: he has to conduct more research than in the observable case and in equi-librium, discloses all the information he obtained. However this extra research can be socially bene-ficial and mandatory disclosure of results can thus be welfare reducing. Finally I identify cases where the sender withholds evidence and for which mandatory disclosure rules become more attractive. In 2002, editors of eleven of th...
Transparency: A Fundamental Social Obligation for Clinical Research .After 60 years devoted to enhan...
Pharmaceutical companies face increasing pressure to bring new treatments to market in order to surv...
This article addresses the problem of restricted access to industry-sponsored clinical trial data. I...
In situations where a biased sender provides verifiable information to a receiver, in order to influ...
In situations where a biased sender provides verifiable information to a receiver, I study how strat...
In situations where a biased sender provides verifiable information to a receiver, I study how strat...
In situations where a biased sender provides verifiable information to a receiver, I study how strat...
Scandals of selective reporting of clinical trial results by pharmaceutical firms have underlined th...
In a model where a sender provides verifiable information to a receiver, in order to influence her, ...
Scandals of selective reporting of clinical trial results by pharmaceutical \u85rms have under-lined...
This paper contributes to the ongoing debate on the reliability of published research. In particular...
We analyze the incentives to disclose intermediate research results. We find that despite the help t...
On the basis of a survey of 7103 active faculty researchers in nine fields, we examine the extent to...
This paper examines the incentives of a firm to invest in information about the quality of its produ...
This dissertation examines the disclosure of research findings in the context of evidence- based med...
Transparency: A Fundamental Social Obligation for Clinical Research .After 60 years devoted to enhan...
Pharmaceutical companies face increasing pressure to bring new treatments to market in order to surv...
This article addresses the problem of restricted access to industry-sponsored clinical trial data. I...
In situations where a biased sender provides verifiable information to a receiver, in order to influ...
In situations where a biased sender provides verifiable information to a receiver, I study how strat...
In situations where a biased sender provides verifiable information to a receiver, I study how strat...
In situations where a biased sender provides verifiable information to a receiver, I study how strat...
Scandals of selective reporting of clinical trial results by pharmaceutical firms have underlined th...
In a model where a sender provides verifiable information to a receiver, in order to influence her, ...
Scandals of selective reporting of clinical trial results by pharmaceutical \u85rms have under-lined...
This paper contributes to the ongoing debate on the reliability of published research. In particular...
We analyze the incentives to disclose intermediate research results. We find that despite the help t...
On the basis of a survey of 7103 active faculty researchers in nine fields, we examine the extent to...
This paper examines the incentives of a firm to invest in information about the quality of its produ...
This dissertation examines the disclosure of research findings in the context of evidence- based med...
Transparency: A Fundamental Social Obligation for Clinical Research .After 60 years devoted to enhan...
Pharmaceutical companies face increasing pressure to bring new treatments to market in order to surv...
This article addresses the problem of restricted access to industry-sponsored clinical trial data. I...